| 0 | ℹ |
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-01-10 | #clinical trial #immunotherapy #lymphoma #relapsed | |
| 0 | ℹ |
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-01-10 | #antibody #clinical trial #immunotherapy #lymphoma #relapse |